ASCO 2023 | PSMA screening in prostate cancer: addressing controversies

Ravi Amrit Madan, MD, National Cancer Institute, Bethesda, MD, addresses the controversies surrounding PSMA PET screening for prostate cancer, emphasizing the importance of patient and provider education. While there have been concerns about underdiagnosis and overdiagnosis, PSMA screening remains an appropriate approach. The addition of MRI imaging has enhanced screening capabilities. It is crucial to have clear discussions after diagnosis, distinguishing between low-grade Gleason six disease that may not require immediate treatment and potentially aggressive cases that necessitate intervention. Robust PSMA screening, coupled with informed decision-making, can help prevent both underdiagnosis and overtreatment, ensuring timely detection of high-risk prostate cancer while avoiding unnecessary interventions for low-risk cases. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.